Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a ...

An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it ...

The oral version of Wegovy has made GLP-1 medicines more accessible and acceptable to many patients who had steered clear of ...

The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two ...

In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe and Jennifer Fakish at Danaher Corporation. They discuss how antibody drug conjugates (ADCs) are transforming cancer ...

Biopharma professionals need to understand today’s job market and how they can stand out to position themselves for success. Three talent acquisition and recruiting experts discussed these topics in a ...

Last month, biopharmas let go or projected they would let go of less than 500 people combined, based on BioSpace estimates, down almost 1,000 from January 2025. Still, competition for open jobs ...

Taiwan’s PharmaEssentia has committed $46 million to build a Puerto Rico drug manufacturing facility to serve the U.S. market ...

The FDA issued a rare Refusal-to-File letter to Moderna over its mRNA-based influenza vaccine application, in an unusual move that sent the biotech’s shares tumbling.

A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company ...